AR121515A1 - Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores - Google Patents

Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores

Info

Publication number
AR121515A1
AR121515A1 ARP210100576A ARP210100576A AR121515A1 AR 121515 A1 AR121515 A1 AR 121515A1 AR P210100576 A ARP210100576 A AR P210100576A AR P210100576 A ARP210100576 A AR P210100576A AR 121515 A1 AR121515 A1 AR 121515A1
Authority
AR
Argentina
Prior art keywords
efficacy
methods
evaluate
compositions
transporter inhibitors
Prior art date
Application number
ARP210100576A
Other languages
English (en)
Spanish (es)
Inventor
Hong Sun
Xiaojun Li
Zafrin Dhali
Haiping Lu
Wilson Wu
Wen Luo
John W Whitaker
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of AR121515A1 publication Critical patent/AR121515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP210100576A 2020-03-06 2021-03-05 Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores AR121515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06

Publications (1)

Publication Number Publication Date
AR121515A1 true AR121515A1 (es) 2022-06-08

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100576A AR121515A1 (es) 2020-03-06 2021-03-05 Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores

Country Status (13)

Country Link
US (1) US12612661B2 (enExample)
EP (1) EP4106872B1 (enExample)
JP (1) JP2023515665A (enExample)
KR (1) KR20230005816A (enExample)
CN (1) CN115515680A (enExample)
AR (1) AR121515A1 (enExample)
AU (1) AU2021231683A1 (enExample)
BR (1) BR112022017770A2 (enExample)
CA (1) CA3174572A1 (enExample)
IL (1) IL296168A (enExample)
MX (1) MX2022010816A (enExample)
TW (1) TW202146660A (enExample)
WO (1) WO2021178166A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6945457B1 (en) * 1996-05-10 2005-09-20 Transaction Holdings Ltd. L.L.C. Automated transaction machine
JP4198582B2 (ja) * 2003-12-02 2008-12-17 独立行政法人科学技術振興機構 タンタルオキシナイトライド酸素還元電極触媒
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2008065544A2 (en) * 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
AU2008222563A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
MX2013008846A (es) 2011-01-31 2014-02-11 Denovo Biomarkers Inc Metodo para descubrir biomarcadores farmacogenomicos.
WO2012156515A1 (en) * 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
US10202652B2 (en) 2011-06-08 2019-02-12 Denovo Biopharma (Hangzhou) Ltd. Co. Methods and compositions of predicting activity of retinoid X receptor modulator
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
PL3117012T5 (pl) * 2014-03-14 2026-03-16 Caredx, Inc. Sposoby monitorowania terapii immunosupresyjnych u biorcy przeszczepu

Also Published As

Publication number Publication date
EP4106872A1 (en) 2022-12-28
US20230193388A1 (en) 2023-06-22
BR112022017770A2 (pt) 2022-11-29
IL296168A (en) 2022-11-01
JP2023515665A (ja) 2023-04-13
AU2021231683A1 (en) 2022-09-22
TW202146660A (zh) 2021-12-16
KR20230005816A (ko) 2023-01-10
MX2022010816A (es) 2022-12-13
EP4106872B1 (en) 2026-07-15
CN115515680A (zh) 2022-12-23
CA3174572A1 (en) 2021-09-10
WO2021178166A1 (en) 2021-09-10
US12612661B2 (en) 2026-04-28
EP4106872A4 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
AR119676A1 (es) Receptores de antígenos quiméricos de gprc5d y células que los expresan
CL2019000973A1 (es) Método y sistemas para la indexación de datos bioinformáticos.
CO2022013827A2 (es) Compuestos y métodos para modular el empalme
MX2020002542A (es) Variantes de interleucina-18 y metodos de uso.
ECSP19031545A (es) Composiciones de células t con car anti-bcma
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX2020012561A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas.
CL2018002467A1 (es) El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint
CL2022002779A1 (es) Compuestos y métodos para modular el proceso de corte y empalme
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
MX347514B (es) Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
MX2018003301A (es) Inhibidores de pcna.
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
BR112018002503A2 (pt) comutador em cascata entre pluralidades de lnas
EP4062260A4 (en) VEHICLE COMPUTER COOLING ARCHITECTURE
CO2023015915A2 (es) Anticuerpos anti-ccr8
MX383670B (es) Nuevos marcadores de la diferenciación de th17 para el acné y usos de los mismos.
CO2022000705A2 (es) Receptor de antígeno quimérico (car) anti-hk2
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
BR112018009463A2 (pt) ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
MX381948B (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.